Expanding the use of Alzheimer's blood tests is crucial to usher in a new era of precision medicine and bring Alzheimer's ...

Data provided by UNLV researchers helped secure FDA approval for a new blood test to detect Alzheimer’s disease.

Fujirebio Diagnostics Inc.’s Alzheimer’s disease assay received the U.S. FDA’s first clearance for a blood test for the debilitating neurodegenerative disease. Fujirebio’s Lumipulse G ...

Quest Diagnostics has signed up to offer a blood test that can help diagnose Alzheimer’s disease, following its FDA clearance earlier this year. Developed by Fujirebio, the Lumipulse G test ...

But the Fujirebio Diagnostics test is the first one cleared by the FDA. “Blood-based biomarkers are reshaping how we identify and understand Alzheimer’s disease,” Carrillo said.

The new test, from Fujirebio Diagnostics, Inc., identifies a sticky brain plaque, known as beta-amyloid, that is a key marker for Alzheimer’s.

On Friday, the Food and Drug Administration (FDA) cleared the first blood test for the disorder. Fujirebio Diagnostics' Lumipulse measures the ratio of two proteins that correlate with the ...

The Fujirebio test offering extends this portfolio to include an FDA-cleared option for use in specialized care settings. "Our goal is to advance access to quality and innovative blood-based tests ...